China NMPA Drug Inspection - Hangzhou Minsheng Pharmaceutical Co., Ltd. - Spironolactone tablets
China NMPA drug inspection for Hangzhou Minsheng Pharmaceutical Co., Ltd. published January 22, 2020. Drug: Spironolactone tablets. The Ningxia Drug Administration in China published the findings of its 2018 drug sampling inspections on January 22, 202
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Hangzhou Minsheng Pharmaceutical Co., Ltd. published January 22, 2020. Drug: Spironolactone tablets. The Ningxia Drug Administration in China published the findings of its 2018 drug sampling inspections on January 22, 202
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox